Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Marc L. Citron
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy as (Neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Related publications
Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer
Cancer
Cancer Research
Oncology
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Meta-Analysis
Scientific Reports
Multidisciplinary
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE
Cancer
Cancer Research
Oncology
Expression of Growth Factor Receptor Family Before and After Targeted Therapy in Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Tissues
Korean Journal of Clinical Oncology
Ado-Trastuzumab Emtansine Targets Hepatocytes via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity
Molecular Cancer Therapeutics
Cancer Research
Oncology
FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History
Nowotwory
Cancer Research
Oncology
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines
BMC Health Services Research
Health Policy
